DK0871495T3 - Omdirigering af cellulær immunitet med receptorkimærer - Google Patents
Omdirigering af cellulær immunitet med receptorkimærerInfo
- Publication number
- DK0871495T3 DK0871495T3 DK96904498T DK96904498T DK0871495T3 DK 0871495 T3 DK0871495 T3 DK 0871495T3 DK 96904498 T DK96904498 T DK 96904498T DK 96904498 T DK96904498 T DK 96904498T DK 0871495 T3 DK0871495 T3 DK 0871495T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- infective agent
- chimeric receptors
- target
- receptor
- Prior art date
Links
- 230000007969 cellular immunity Effects 0.000 title 1
- 108700010039 chimeric receptor Proteins 0.000 abstract 6
- 230000001524 infective effect Effects 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39417695A | 1995-02-24 | 1995-02-24 | |
| PCT/US1996/001056 WO1996025953A1 (en) | 1995-02-24 | 1996-01-25 | Redirection of cellular immunity by receptor chimeras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0871495T3 true DK0871495T3 (da) | 2005-10-17 |
Family
ID=23557882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96904498T DK0871495T3 (da) | 1995-02-24 | 1996-01-25 | Omdirigering af cellulær immunitet med receptorkimærer |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0871495B1 (fi) |
| JP (1) | JP4170390B2 (fi) |
| KR (1) | KR100490099B1 (fi) |
| AT (1) | ATE297986T1 (fi) |
| AU (1) | AU708339B2 (fi) |
| CA (1) | CA2209300C (fi) |
| CZ (1) | CZ295428B6 (fi) |
| DE (1) | DE69634855T2 (fi) |
| DK (1) | DK0871495T3 (fi) |
| ES (1) | ES2245456T3 (fi) |
| FI (1) | FI119757B (fi) |
| HU (1) | HU225688B1 (fi) |
| NO (1) | NO323632B1 (fi) |
| NZ (2) | NZ302513A (fi) |
| PT (1) | PT871495E (fi) |
| RU (1) | RU2167676C2 (fi) |
| WO (1) | WO1996025953A1 (fi) |
| ZA (1) | ZA961477B (fi) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998039418A1 (en) * | 1997-03-07 | 1998-09-11 | Ariad Gene Therapeutics, Inc. | New applications of gene therapy technology |
| KR100620481B1 (ko) * | 1996-10-23 | 2006-09-06 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 |
| EA201001190A1 (ru) * | 1998-09-23 | 2011-04-29 | Займодженетикс, Инк. | Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков |
| GB9908807D0 (en) * | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| IL137419A0 (en) * | 2000-07-20 | 2001-07-24 | Yissum Res Dev Co | Nk cells activating receptors and their therapeutic and diagnostic uses |
| WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| KR102243575B1 (ko) | 2010-12-09 | 2021-04-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| ES2719495T3 (es) | 2012-05-07 | 2019-07-10 | Dartmouth College | Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos |
| ES2786263T3 (es) | 2012-07-13 | 2020-10-09 | Univ Pennsylvania | Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| KR102313997B1 (ko) | 2013-02-20 | 2021-10-20 | 노파르티스 아게 | 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료 |
| EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| AU2014366047B2 (en) | 2013-12-19 | 2021-03-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| ES2837856T3 (es) * | 2013-12-20 | 2021-07-01 | Hutchinson Fred Cancer Res | Moléculas efectoras quiméricas etiquetadas y receptores de las mismas |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| HRP20240874T1 (hr) | 2014-04-07 | 2024-10-11 | Novartis Ag | Liječenje raka korištenjem kimernog antigenskog receptora anti-cd19 |
| CA2955154C (en) | 2014-07-21 | 2023-10-31 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| AU2015292811B2 (en) | 2014-07-21 | 2019-12-19 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
| MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| AU2015317608B2 (en) | 2014-09-17 | 2021-03-11 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN113789336A (zh) * | 2014-09-19 | 2021-12-14 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| RU2743657C2 (ru) | 2014-10-08 | 2021-02-20 | Новартис Аг | Биомаркеры, прогнозирующие способность к терапевтическому ответу на терапию химерным рецептором антигена, и их применение |
| WO2016109410A2 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| RU2752918C2 (ru) | 2015-04-08 | 2021-08-11 | Новартис Аг | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19 |
| EP3283619B1 (en) | 2015-04-17 | 2023-04-05 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| WO2017004252A1 (en) | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
| CN109476722A (zh) | 2015-07-21 | 2019-03-15 | 诺华股份有限公司 | 用于改善免疫细胞的功效和扩张的方法 |
| GB201513540D0 (en) * | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| IL295858A (en) | 2015-12-04 | 2022-10-01 | Novartis Ag | Preparations and methods for immuno-oncology |
| JP7082055B2 (ja) | 2015-12-22 | 2022-06-07 | ノバルティス アーゲー | 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体 |
| TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| EP3601561A2 (en) | 2017-03-22 | 2020-02-05 | Novartis AG | Compositions and methods for immunooncology |
| EP3697436A1 (en) | 2017-10-18 | 2020-08-26 | Novartis AG | Compositions and methods for selective protein degradation |
| CN112119157A (zh) | 2018-03-06 | 2020-12-22 | 宾夕法尼亚大学董事会 | 前列腺特异性膜抗原car及其使用方法 |
| SG11202011830SA (en) | 2018-06-13 | 2020-12-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
| US11975026B2 (en) | 2019-11-26 | 2024-05-07 | Novartis Ag | CD19 and CD22 chimeric antigen receptors and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2096749T3 (es) * | 1990-12-14 | 1997-03-16 | Cell Genesys Inc | Cadenas quimericas para vias de transduccion de señal asociada a un receptor. |
| US5912170A (en) * | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
| IL101147A (en) * | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Change of direction of cellular immunity by chimera receptors |
| US5439819A (en) * | 1993-08-27 | 1995-08-08 | The Regents Of The University Of California | Chimeric protein tyrosine kinases |
-
1996
- 1996-01-25 JP JP52568596A patent/JP4170390B2/ja not_active Expired - Lifetime
- 1996-01-25 HU HU9801873A patent/HU225688B1/hu unknown
- 1996-01-25 DK DK96904498T patent/DK0871495T3/da active
- 1996-01-25 PT PT96904498T patent/PT871495E/pt unknown
- 1996-01-25 DE DE69634855T patent/DE69634855T2/de not_active Expired - Lifetime
- 1996-01-25 RU RU97115769/14A patent/RU2167676C2/ru active
- 1996-01-25 ES ES96904498T patent/ES2245456T3/es not_active Expired - Lifetime
- 1996-01-25 NZ NZ302513A patent/NZ302513A/xx not_active IP Right Cessation
- 1996-01-25 AU AU48588/96A patent/AU708339B2/en not_active Expired
- 1996-01-25 NZ NZ337002A patent/NZ337002A/en not_active IP Right Cessation
- 1996-01-25 CA CA2209300A patent/CA2209300C/en not_active Expired - Lifetime
- 1996-01-25 KR KR1019970705850A patent/KR100490099B1/ko not_active IP Right Cessation
- 1996-01-25 AT AT96904498T patent/ATE297986T1/de active
- 1996-01-25 WO PCT/US1996/001056 patent/WO1996025953A1/en active IP Right Grant
- 1996-01-25 EP EP96904498A patent/EP0871495B1/en not_active Expired - Lifetime
- 1996-01-25 CZ CZ19972599A patent/CZ295428B6/cs not_active IP Right Cessation
- 1996-02-23 ZA ZA9601477A patent/ZA961477B/xx unknown
-
1997
- 1997-08-21 FI FI973437A patent/FI119757B/fi not_active IP Right Cessation
- 1997-08-22 NO NO19973864A patent/NO323632B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU4858896A (en) | 1996-09-11 |
| ES2245456T3 (es) | 2006-01-01 |
| KR100490099B1 (ko) | 2005-11-28 |
| EP0871495A1 (en) | 1998-10-21 |
| FI973437A (fi) | 1997-10-16 |
| EP0871495A4 (en) | 2000-09-13 |
| NZ337002A (en) | 2005-07-29 |
| ATE297986T1 (de) | 2005-07-15 |
| FI973437A0 (fi) | 1997-08-21 |
| AU708339B2 (en) | 1999-08-05 |
| KR19980702450A (ko) | 1998-07-15 |
| CA2209300C (en) | 2011-06-28 |
| EP0871495B1 (en) | 2005-06-15 |
| NO323632B1 (no) | 2007-06-18 |
| NZ302513A (en) | 1999-11-29 |
| RU2167676C2 (ru) | 2001-05-27 |
| CZ259997A3 (cs) | 1998-05-13 |
| FI119757B (fi) | 2009-03-13 |
| NO973864D0 (no) | 1997-08-22 |
| HUP9801873A2 (hu) | 1998-11-30 |
| JPH11505409A (ja) | 1999-05-21 |
| WO1996025953A1 (en) | 1996-08-29 |
| HUP9801873A3 (en) | 2000-08-28 |
| CZ295428B6 (cs) | 2005-08-17 |
| ZA961477B (en) | 1997-02-03 |
| HU225688B1 (en) | 2007-06-28 |
| CA2209300A1 (en) | 1996-08-29 |
| PT871495E (pt) | 2005-10-31 |
| DE69634855D1 (de) | 2005-07-21 |
| NO973864L (no) | 1997-10-22 |
| JP4170390B2 (ja) | 2008-10-22 |
| DE69634855T2 (de) | 2006-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0871495T3 (da) | Omdirigering af cellulær immunitet med receptorkimærer | |
| NO973863L (no) | Omdirigering av cellulær immunitet med protein-tyrosin-kinase-kimærer | |
| ATE308888T1 (de) | Gezielte zell-lyse von hiv-infizierten zellen mit chimären cd4 rezeptortragenden zellen | |
| DK0574512T3 (da) | Omdirigering af cellulær immunitet med receptorkimærer | |
| DK0804552T3 (da) | Omdirigering af cellulær immunitet ved hjælp af receptorkimærer |